

# **POSTER PRESENTATION**

**Open Access** 

# First report of OXA-48 carbapenemase-producing Escherichia coli in Taiwan

Y Jao<sup>1\*</sup>, P-S Lee<sup>2</sup>, C-T Hung<sup>1</sup>, C-F Wang<sup>2</sup>, MH Hsieh<sup>1,3</sup>, C-Y Lin<sup>1,3</sup>, Y-H Chen<sup>1,3</sup>, P-L Lu<sup>2,3</sup>

From 3rd International Conference on Prevention and Infection Control (ICPIC 2015) Geneva, Switzerland. 16-19 June 2015

## Introduction

Carbapenems are the last-line antibiotic in treating Enterobacteriaceae because its broad-spectrum antibacterial ability, high bactericidal activity and good stability to  $\beta$ -lactamases. However, carbapenem-resistant Enterobacteriaceae (CRE) infection increased all over the world in recent years. The challenge of carbapenems in treating Enterobacteriaceae is increasing.

# **Objectives**

A 55-year old woman who had been diagnosed with cancer and had received multiple courses of chemotherapy in Vietnam, visited our hospital for a second opinion in June 2014.

Left breast tumor with non-discharge necrotic tissue was presented at admission. The laboratory examination demonstrated WBC 6300/uL, Hb 12.1g/dL and PLT 103000/uL. Specimen from left breast wound grew Escherichia coli, which resistant to carbapenems, broadspectrum  $\beta$ -lactams and fluoroquinolones. There was no inflammation reaction caused by the pathogen. During hospitalization, she did not receive antimicrobial therapy effective to the pathogen.

### **Methods**

We found that this *Escherichia coli* had the presentation of carbapenemase via modified Hodge test. Polymerase chain reaction and DNA sequencing was performed to test if Carbapenemase (blaKPC, blaNDM, blaIPM, blaVIM, blaOXA) or  $\beta$ -lactamases (SH, TEM, OXA, GES, CTX-M) presents.

### **Results**

Resistance genes of blaOXA-48 and CTX-M-1-group were found. Besides, this *Escherichia coli* also presented with loss of outer membrane protein A and F. With multilocus sequence typing (MLST) analysis, this *Escherichia coli* is ST-405.

### **Conclusion**

To our knowledge, this is the first OXA-48 carbapenemase producing *Escherichia coli* isolated in Taiwan, though it's originated from Vietnam. It's resistance profile is similar to other OXA-48 carbapenemase producing *Escherichia coli* isolated from Japan and France. According to this finding, *Escherichia coli* acquiring OXA-48 carbapenemase may had spread to Southeastern Asia. In order to prevent the transmission of CRE, the detection of carbapenemase in Enterobacteriaceae is important.

## **Disclosure of interest**

None declared.

### Authors' details

<sup>1</sup>Department of Infection Control, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China. <sup>2</sup>Clinical Microbiology Laboratory, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China. <sup>3</sup>Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China.

Published: 16 June 2015

doi:10.1186/2047-2994-4-S1-P126

Cite this article as: Jao et al.: First report of OXA-48 carbapenemaseproducing Escherichia coli in Taiwan. Antimicrobial Resistance and Infection Control 2015 4(Suppl 1):P126.

<sup>1</sup>Department of Infection Control, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, Province of China Full list of author information is available at the end of the article

